Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2041

Annual patent cliff calendar for 2041 — US pharmaceutical patents by expiration date.

Patents
2,000

Quick answer

2,000 indexed pharmaceutical patents have expiration dates in 2041. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 10899732

    Substituted benzamides useful as sodium channel blockers

    Xenon Pharmaceuticals Inc. · Granted Tue Jan 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10898595

    Core-satellite nanocomposites for MRI and photothermal therapy

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jan 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10900041

    Antisense oligonucleotides for use in treating Alzheimer's disease

    ProQR Therapeutics II B.V. · Granted Tue Jan 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10906940

    Antimicrobial peptides, pharmaceutical compositions, and methods of use thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10907175

    Isolated human cell with an inactivated glucocorticoid receptor gene

    Sangamo Therapeutics, Inc. · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10905752

    VEGFR-2 targeting DNA vaccine for combination therapy

    Vaximm AG · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10905769

    Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10906913

    NMDA receptor modulators and uses thereof

    Northwestern University · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10906914

    Furoquinolinediones as inhibitors of TDP2

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10907158

    Antisense antibacterial compounds and methods

    The Board of Regents of the University of Texas System · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10907154

    Exon skipping compositions for treating muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10906985

    Targeted engineered interferon and uses thereof

    Orionis Biosciences, Inc · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10907160

    Methods for reducing LRRK2 expression

    Ionis Pharmaceuticals, Inc. · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10905666

    Methods and compositions for treating conditions associated with an abnormal inflammatory response

    First Wave Bio, Inc. · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10907151

    Compositions and methods for treating or preventing lupus

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10907124

    Biomimetic membranes, methods of manufacture and uses thereof

    The Regents of the University of California · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10906916

    Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors

    Valo Early Discovery, Inc. · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10906928

    Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus

    Atea Pharmaceuticals, Inc. · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10906891

    Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide

    Vertex Pharmaceuticals Incorporated · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10906896

    Compositions and methods for inhibiting kinases

    Inhibikase Therapeutics, Inc. · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10905784

    Radiolabeled anti-LAG3 antibodies for immuno-PET imaging

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10906864

    Nitroalkene non steroidal anti-inflammatory drugs (NA-NSAIDS) and methods of treating inflammation related conditions

    INSTITUT PASTEUR DE MONTEVIDEO · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10905782

    Compositions for enhancing transport of molecules into cells

    Sarepta Therapeutics, Inc. · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10905770

    Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases

    MacRegen, Inc. · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10905775

    Particulate constructs for release of active agents

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10907170

    Increasing levels of nicotinic alkaloids in plants

    22ND CENTURY LIMITED, LLC · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10905755

    Vaccines for human papilloma virus and methods for using the same

    Inovio Pharmaceuticals, Inc. · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10905768

    Heterocyclic degronimers for target protein degradation

    C4 THERAPEUTICS, INC. · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10905721

    Device and methods for platelet lysis or activation

    Regenexx, LLC · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10905736

    Ezetimibe-associated ApoA-I mimetic peptides showing enhanced synergism

    The Regents of the University of California · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10905709

    Modified antisense oligomers for exon inclusion in spinal muscular atrophy

    Sarepta Therapeutics, Inc. · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10905692

    Combination therapy for treating malignancies

    Agios Pharmaceuticals, Inc. · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10905683

    Compositions and uses of amidine derivatives

    BioCryst Pharmaceuticals, Inc. · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10905690

    Treatment of congenital adrenal hyperplasia

    Neurocrine Biosciences, Inc. · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10905693

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10906871

    Processes for making, and methods of using, glycopyrronium compounds

    Dermira, Inc. · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10906898

    Cocrystal

    Takeda Pharmaceutical Company Limited · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10905710

    Particles with RNA cleaving nucleobase polymers and uses for managing inflammatory disorders

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. CA 3147876

    DERIVES DE LA 1,2,4-OXADIAZOL-5-ONE POUR LE TRAITEMENT DU CANCER

    BASILEA PHARM INT AG [CH] · Granted Thu Feb 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10913946

    RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy

    BIOMARIN TECHNOLOGIES B.V. · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10913790

    Compositions of, and methods for, alpha-1 anti trypsin Fc fusion molecules

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10913888

    Nanotube mediation of degradative chemicals for oil-field application

    MOLECULAR REBAR DESIGN, LLC · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10913798

    Modulators of ROR1-ROR2 binding

    The Regents of the University of California · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10913761

    2,7-dibromospiro[fluorene-9,4′-piperidine] compounds

    Vertex Pharmaceuticals Incorporated · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10913740

    JAK kinase inhibitor compounds for treatment of respiratory disease

    Theravance Biopharma R&D IP, LLC · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10913750

    Tubulin-binding compounds, compositions and uses related thereto

    The Regents of the University of California · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10913726

    Centrally active and orally bioavailable antidotes for organophosphate exposure and methods for making and using them

    The Regents of the University of California · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10913711

    Potent and selective inhibitors of monoamine transporters; method of making; and use thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2041?

2,000 published patents in our USPTO index have expiration dates falling in calendar year 2041.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.